World's Best Scientists 2026 revealed!
Priti Hegde

Priti Hegde

D-Index & Metrics

Biology and Biochemistry

D-Index
53
Citations
35923
World Ranking
15872
National Ranking
6591

Priti Hegde publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Priti Hegde sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 243 publications — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Priti Hegde D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Priti Hegde sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 53 D-Index — 19th percentile

19% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

Priti Hegde is affiliated with Genentech in the United States and has a research focus primarily in the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their work spans diverse subfields including Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Immunology, and Molecular Biology.

The main topics addressed in their research include:

  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Treatments and Mutations
  • Colorectal Cancer Treatments and Studies
  • CAR-T cell therapy research
  • Genetic factors in colorectal cancer
  • Bladder and Urothelial Cancer Treatments

Hegde has published extensively, with a notable presence in journals such as the Journal of Clinical Oncology, Cancer Research, PLoS ONE, Nature Communications, and Cancer Cell. The frequency of publications in these venues are:

  • Journal of Clinical Oncology: 6 publications
  • Cancer Research: 5 publications
  • PLoS ONE: 4 publications
  • Nature Communications: 3 publications
  • Cancer Cell: 2 publications

Among the recent papers authored or co-authored by Hegde are:

  • "Top 10 Challenges in Cancer Immunotherapy," 2020, Immunity
  • "Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade," 2020, Cancer Cell
  • "Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin," 2020, PLoS ONE
  • "High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade," 2020, Nature Medicine
  • "Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy," 2020, Science Translational Medicine

The scientist frequently collaborates with the following co-authors:

  • David Fabrizio
  • Sanjeev Mariathasan
  • Brian M. Alexander
  • Garrett M. Frampton
  • Thomas Powles

Best Publications

  • Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

    Roy S. Herbst;Jean Charles Soria;Marcin Kowanetz;Gregg D. Fine

  • TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

    Sanjeev Mariathasan;Shannon J. Turley;Dorothee Nickles;Alessandra Castiglioni

  • MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

    Thomas Powles;Joseph Paul Eder;Gregg D. Fine;Fadi S. Braiteh

  • Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.

    Thomas Powles;Ignacio Durán;Michiel S van der Heijden;Yohann Loriot

  • Top 10 Challenges in Cancer Immunotherapy

    Priti S. Hegde;Daniel S. Chen

  • A Concise Guide to cDNA Microarray Analysis

    P. Hegde;R. Qi;K. Abernathy

  • Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

    David F. McDermott;Mahrukh A. Huseni;Michael B. Atkins;Robert J. Motzer

  • Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

    David R. Gandara;Sarah M. Paul;Marcin Kowanetz;Erica Schleifman

  • The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition.

    Priti S. Hegde;Vaios Karanikas;Stefan Evers

  • Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

    Jeffrey J. Wallin;Johanna C. Bendell;Roel Funke;Mario Sznol

  • Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

    David F. McDermott;Jeffrey A. Sosman;Mario Sznol;Christophe Massard

  • Activation of Peroxisome Proliferator–Activated Receptor (PPAR)δ Promotes Reversal of Multiple Metabolic Abnormalities, Reduces Oxidative Stress, and Increases Fatty Acid Oxidation in Moderately Obese Men

    Ulf Risérus;Dennis Sprecher;Tony Johnson;Eric Olson

  • A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

    Wenle Xia;Sarah Bacus;Priti Hegde;Intisar Husain

  • High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade.

    Kobe C. Yuen;Li-Fen Liu;Vinita Gupta;Shravan Madireddi

  • Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics

    Priti S. Hegde;Jeffrey J. Wallin;Christoph Mancao

  • Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade

    Robert J. Motzer;Romain Banchereau;Habib Hamidi;Thomas Powles

  • Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy.

    Maud Mayoux;Andreas Roller;Vesna Pulko;Stefano Sammicheli

  • Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial

    Thomas Sandmann;Richard Bourgon;Josep Garcia;Congfen Li

  • Interplay of transcriptomics and proteomics

    Priti S Hegde;Ian R White;Christine Debouck

  • NF-κB Mediates the Stimulation of Cytokine and Chemokine Expression by Human Articular Chondrocytes in Response to Fibronectin Fragments

    Judit I. Pulai;Hong Chen;Hee Jeong Im;Sanjay Kumar

Frequent Co-Authors

Thomas Powles
Thomas Powles Queen Mary University of London
Nicholas J. Vogelzang
Nicholas J. Vogelzang University of Nevada Reno
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
David R. Gandara
David R. Gandara University of California, Davis
Joaquim Bellmunt
Joaquim Bellmunt Beth Israel Deaconess Medical Center
Scott N. Gettinger
Scott N. Gettinger Yale University
Ira Mellman
Ira Mellman Parker Institute for Cancer Immunotherapy
Naiyer A. Rizvi
Naiyer A. Rizvi Columbia University Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Biology and Biochemistry opens doors to a wide range of online degree options and career routes in the health sciences. For example, if you are interested in nutrition and wellness, you can consider a holistic nutrition degree that emphasizes a whole-body approach to health.

Broader career opportunities in healthcare leadership can be accessed through online healthcare MBA programs, where you’ll develop the business and management skills essential for the fast-changing medical field.

Those with an eye for detail may be interested in medical data, where becoming a certified professional coder is a popular certification. Understanding the medical coding jobs salary landscape can help guide your next steps, as this field is in high demand and offers strong earning potential.

Ultimately, whether your interest lies in research, clinical practice, healthcare management, or coding, exploring these online options broadens your professional outlook and helps you find the right career path.

Best Scientists Citing Priti Hegde

Trending Scientists

Recently Published Articles